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Background
Repetitive transcranial magnetic stimulation (rTMS) non-
invasively triggers action potentials in underlying brain
cortex intended for therapeutic benefit. Currently mar-
keted for refractory depression, rTMS is under investiga-
tion for treating several neurological conditions including
pain. Facial neuropathic pain (NP) appears to respond well
to rTMS [1]. The primary motor cortex (M1) is estab-
lished as the best site to stimulate to relieve pain, but the
best target within M1 remains unknown [1,2]. MRI gui-
dance of rTMS permits repeated precise application to
specific targets. The aim of this study was to compare pain
relief obtained by applying MRI-guided rTMS to the M1
representation of subjects’ painful face vs. to adjacent M1
cortex innervating their non-painful hand.
Materials and methods
In this ongoing randomized, single-blinded, placebo-con-
trolled, cross-over study, eight adults with facial NP pro-
vided informed consent for head MRI and rTMS. Subjects
undertook the 3 study phases in random order. In one
phase, rTMS was applied to the contralateral M1 repre-
sentation of their painful face. In the others, rTMS was
applied to the adjacent hand area, or sham-rTMS was
administered to the hand area using a spacer below the
coil. In each phase, 1500 stimuli were administered using
a Nexstim NBS 3.2 with a double 70mm coil. Five-second
trains of 10 Hz pulses were applied at 80% of resting
motor threshold with 55 second inter-train intervals. Each
study-phase involved recording baseline data for 3 days, 5
consecutive daily sessions of rTMS, followed by 3 washout
weeks. The primary outcome was change in the 0-10
numeric pain rating score. Secondary outcomes measured
physical and mental functioning using the SF-36, McGill
pain questionnaire and Beck depression Inventory.
Results
Among the 8 subjects studied so far, 4 had V1 postherpe-
tic neuralgia, 2 had ocular NP, and one each had trigem-
inal neuralgia and idiopathic facial pain. Reductions in
mean pain intensity were >20% on treatment days 3-5
during both active treatments, but not during sham treat-
ment. Pain reverted to baseline within two weeks after
ending treatment. 3/8 subjects had pain reductions >30%
when the cortex innervating their hand was stimulated
and 2/8 had reductions >30% when cortex innervating
their face was stimulated. Secondary outcomes did not
change and there were no significant adverse events.
Conclusions
These preliminary results corroborate the efficacy of rTMS
for facial NP. Recruitment is ongoing to test the hypoth-
esis that stimulating adjacent healthy cortex may relieve
pain better than stimulating cortex representing the pain-
ful face [3].
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